Qiu-Yue Lou1,2, Zhen Li1,2, Ying Teng1,2, Qiao-Mei Xie1,2, Man Zhang1,2, Shun-Wei Huang1,2, Wen-Fei Li3, Yang-Fan Chen4, Fa-Ming Pan1,2, Sheng-Qian Xu4, Jing Cai4, Shuang Liu4, Jin-Hui Tao5, Sheng-Xiu Liu6, Hai-Liang Huang7, Fang Wang8, Hai-Feng Pan1,2, Hong Su1,2, Zhi-Wei Xu9, Wen-Biao Hu10, Yan-Feng Zou11,12. 1. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, No. 81, Meishan Rd, Shushan District, Hefei, 230032, Anhui, China. 2. The Key Laboratory of Anhui Medical Autoimmune Diseases, Hefei, 230032, Anhui, China. 3. Department of Psychiatry, Anhui Mental Health Center, Hefei, 230022, Anhui, China. 4. Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. 5. Department of Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, 230001, Anhui, China. 6. Institute of Dermatology and Department of Dermatology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. 7. Department of Biochemistry and Molecular Biology, School of Basic Medicine, Anhui Medical University, Hefei, 230032, Anhui, China. 8. Department of Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, Anhui, China. 9. School of Public Health and Social Work, Institute of Health and Biomedical Innovation, Queensland University of Technology, Victoria Park, Brisbane, Queensland, 4059, Australia. 10. School of Public Health and Social Work, Institute of Health and Biomedical Innovation, Queensland University of Technology, Victoria Park, Brisbane, Queensland, 4059, Australia. w2.hu@qut.edu.au. 11. Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, No. 81, Meishan Rd, Shushan District, Hefei, 230032, Anhui, China. zouyanfeng2015@163.com. 12. The Key Laboratory of Anhui Medical Autoimmune Diseases, Hefei, 230032, Anhui, China. zouyanfeng2015@163.com.
Abstract
OBJECTIVES: To explore the associations of FKBP4 and FKBP5 gene polymorphisms with disease susceptibility, glucocorticoid (GC) efficacy, anxiety, depression, and health-related quality of life (HRQOL) in systemic lupus erythematosus (SLE) patients. METHODS: All subjects were collected from the First and the Second Affiliated Hospital of Anhui Medical University in Hefei, China, during 2011 to 2015. In the case-control study, 541 SLE patients and 543 controls were recruited. In the follow-up study, 466 patients completed the 12-week follow-up and then were divided into GC-sensitive and GC-insensitive groups. Genotyping was determined using Multiplex SNaPshot technique. Data were analyzed using chi-square test and univariate and multivariate logistic regression analyses. RESULTS: rs4713904, rs9368878, and rs7757037 of FKBP5 were associated with depression in SLE patients (rs4713904, PBH = 0.037; rs9368878, PBH = 0.001; rs7757037, PBH = 0.003). Moreover, rs4713904 was associated with GC efficacy in males with SLE (PBH = 0.011). The rs755658 of FKBP5 was associated with improvement in social function (PBH = 0.022) and mental component summary (PBH = 0.028). The rs4713907 of FKBP5 was related to improvement in total score of SF-36, bodily pain, and mental component summary score (all PBH = 0.018). Furthermore, the rs12582595 of FKBP4 was correlated with general health improvement (PBH = 0.033). No associations were seen between FKBP4/FKBP5 gene polymorphisms and SLE susceptibility and anxiety. CONCLUSIONS: FKBP5 gene polymorphisms may be associated with depression and GC efficacy of SLE patients. Meanwhile, the genetic polymorphisms of FKBP4 and FKBP5 genes may be associated with HRQOL improvement in SLE patients. Key Points • FKBP5 gene polymorphisms were associated with depression of SLE patients. • FKBP5 gene polymorphisms were associated with GC efficacy of SLE patients. • FKBP5 gene polymorphisms were associated with HRQOL improvement in SLE patients. • FKBP4 gene polymorphisms were associated with HRQOL improvement in SLE patients.
OBJECTIVES: To explore the associations of FKBP4 and FKBP5 gene polymorphisms with disease susceptibility, glucocorticoid (GC) efficacy, anxiety, depression, and health-related quality of life (HRQOL) in systemic lupus erythematosus (SLE) patients. METHODS: All subjects were collected from the First and the Second Affiliated Hospital of Anhui Medical University in Hefei, China, during 2011 to 2015. In the case-control study, 541 SLE patients and 543 controls were recruited. In the follow-up study, 466 patients completed the 12-week follow-up and then were divided into GC-sensitive and GC-insensitive groups. Genotyping was determined using Multiplex SNaPshot technique. Data were analyzed using chi-square test and univariate and multivariate logistic regression analyses. RESULTS: rs4713904, rs9368878, and rs7757037 of FKBP5 were associated with depression in SLE patients (rs4713904, PBH = 0.037; rs9368878, PBH = 0.001; rs7757037, PBH = 0.003). Moreover, rs4713904 was associated with GC efficacy in males with SLE (PBH = 0.011). The rs755658 of FKBP5 was associated with improvement in social function (PBH = 0.022) and mental component summary (PBH = 0.028). The rs4713907 of FKBP5 was related to improvement in total score of SF-36, bodily pain, and mental component summary score (all PBH = 0.018). Furthermore, the rs12582595 of FKBP4 was correlated with general health improvement (PBH = 0.033). No associations were seen between FKBP4/FKBP5 gene polymorphisms and SLE susceptibility and anxiety. CONCLUSIONS: FKBP5 gene polymorphisms may be associated with depression and GC efficacy of SLE patients. Meanwhile, the genetic polymorphisms of FKBP4 and FKBP5 genes may be associated with HRQOL improvement in SLE patients. Key Points • FKBP5 gene polymorphisms were associated with depression of SLE patients. • FKBP5 gene polymorphisms were associated with GC efficacy of SLE patients. • FKBP5 gene polymorphisms were associated with HRQOL improvement in SLE patients. • FKBP4 gene polymorphisms were associated with HRQOL improvement in SLE patients.
Authors: Susan L Slager; Christine F Skibola; Maria Chiara Di Bernardo; Lucia Conde; Peter Broderick; Shannon K McDonnell; Lynn R Goldin; Naomi Croft; Amy Holroyd; Shelley Harris; Jacques Riby; Daniel J Serie; Neil E Kay; Timothy G Call; Paige M Bracci; Eran Halperin; Mark C Lanasa; Julie M Cunningham; Jose F Leis; Vicki A Morrison; Logan G Spector; Celine M Vachon; Tait D Shanafelt; Sara S Strom; Nicola J Camp; J Brice Weinberg; Estella Matutes; Neil E Caporaso; Rachel Wade; Martin J S Dyer; Claire Dearden; James R Cerhan; Daniel Catovsky; Richard S Houlston Journal: Blood Date: 2012-06-13 Impact factor: 22.113
Authors: Cheryl L Storer; Chad A Dickey; Mario D Galigniana; Theo Rein; Marc B Cox Journal: Trends Endocrinol Metab Date: 2011-08-31 Impact factor: 12.015
Authors: Lisa F Barcellos; Suzanne L May; Patricia P Ramsay; Hong L Quach; Julie A Lane; Joanne Nititham; Janelle A Noble; Kimberly E Taylor; Diana L Quach; Sharon A Chung; Jennifer A Kelly; Kathy L Moser; Timothy W Behrens; Michael F Seldin; Glenys Thomson; John B Harley; Patrick M Gaffney; Lindsey A Criswell Journal: PLoS Genet Date: 2009-10-23 Impact factor: 5.917